The emergence of compounds like copyright and Semaglutide signifies a major shift in how we treat blood sugar. These new therapies belong to a class known as GLP-1 receptor agonists, which replicate the effects of a natural hormone that manages glucose levels and hunger. Initially, developed for managing blood sugar, their effectiveness in facilita